David Escors

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8535292/publications.pdf

Version: 2024-02-01

107 papers	5,316 citations	76196 40 h-index	95083 68 g-index
123 all docs	123 docs citations	123 times ranked	8256 citing authors

#	Article	IF	Citations
1	Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential. Archivum Immunologiae Et Therapiae Experimentalis, 2010, 58, 107-119.	1.0	262
2	The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nature Immunology, 2014, 15, 965-972.	7.0	243
3	PDâ€Ł1 coâ€stimulation contributes to ligandâ€induced T cell receptor downâ€modulation on CD8 ⁺ T cells. EMBO Molecular Medicine, 2011, 3, 581-592.	3.3	234
4	A sestrin-dependent Erkâ€“Jnkâ€“p38 MAPK activation complex inhibits immunity during aging. Nature Immunology, 2017, 18, 354-363.	7.0	223
5	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
6	Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA Synthesis. Journal of Virology, 2006, 80, 10900-10906.	1.5	198
7	PD1 signal transduction pathways in T cells. Oncotarget, 2017, 8, 51936-51945.	0.8	191
8	The intracellular signalosome of PD-L1 in cancer cells. Signal Transduction and Targeted Therapy, 2018, 3, 26.	7.1	174
9	The Membrane M Protein Carboxy Terminus Binds to Transmissible Gastroenteritis Coronavirus Core and Contributes to Core Stability. Journal of Virology, 2001, 75, 1312-1324.	1.5	162
10	Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome. Journal of Virology, 2002, 76, 11518-11529.	1.5	145
11	Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> â€Ł1/ <scp>PD</scp> â€1 blockade therapy. EMBO Molecular Medicine, 2019, 11, e10293.	3.3	145
12	Role of non-classical MHC class I molecules in cancer immunosuppression. OncoImmunology, 2013, 2, e26491.	2.1	131
13	HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. Journal of Virology, 2010, 84, 5627-5636.	1.5	129
14	Targeting dendritic cell signaling to regulate the response to immunization. Blood, 2008, 111, 3050-3061.	0.6	119
15	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
16	Nonintegrating Lentivector Vaccines Stimulate Prolonged T-Cell and Antibody Responses and Are Effective in Tumor Therapy. Journal of Virology, 2009, 83, 3094-3103.	1.5	82
17	Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles. Biomaterials, 2018, 170, 95-115.	5.7	81
18	Understanding LAG-3 Signaling. International Journal of Molecular Sciences, 2021, 22, 5282.	1.8	78

#	Article	IF	Citations
19	Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy. New Journal of Science, 2014, 2014, 1-25.	1.0	75
20	Construction of stable packaging cell lines for clinical lentiviral vector production. Scientific Reports, 2015, 5, 9021.	1.6	74
21	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Therapy, 2014, 21, 262-271.	2.3	73
22	Pseudaminic Acid on Campylobacter jejuni Flagella Modulates Dendritic Cell IL-10 Expression via Siglec-10 Receptor: A Novel Flagellin-Host Interaction. Journal of Infectious Diseases, 2014, 210, 1487-1498.	1.9	70
23	Organization of Two Transmissible Gastroenteritis Coronavirus Membrane Protein Topologies within the Virion and Core. Journal of Virology, 2001, 75, 12228-12240.	1.5	68
24	Transmissible Gastroenteritis Coronavirus Packaging Signal Is Located at the 5â€² End of the Virus Genome. Journal of Virology, 2003, 77, 7890-7902.	1.5	68
25	Intratumoral administration of mRNA encoding a fusokine consisting of IFN-Î² and the ectodomain of the TGF-Î² receptor II potentiates antitumor immunity. Oncotarget, 2014, 5, 10100-10113.	0.8	66
26	Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigenâ€specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 84-95.	6.7	62
27	A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget, 2014, 5, 7843-7857.	0.8	62
28	Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 328-343.	0.6	61
29	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	1.7	60
30	Ex vivogeneration of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget, 2015, 6, 12369-12382.	0.8	59
31	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1631.	1.8	59
32	A Novel Sorting Signal for Intracellular Localization Is Present in the S Protein of a Porcine Coronavirus but Absent from Severe Acute Respiratory Syndrome-associated Coronavirus. Journal of Biological Chemistry, 2004, 279, 43661-43666.	1.6	52
33	Phosphorylation and subcellular localization of transmissible gastroenteritis virus nucleocapsid protein in infected cells. Journal of General Virology, 2005, 86, 2255-2267.	1.3	52
34	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget, 2015, 6, 27160-27175.	0.8	51
35	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	3.2	51
36	Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Translational Medicine, 2017, 5, 385-385.	0.7	50

#	Article	IF	Citations
37	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology, 2020, 11, 441.	1.6	48
38	Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70. Journal of Immunology, 2013, 191, 1976-1983.	0.4	47
39	Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 224-235.	0.5	45
40	PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. OncoImmunology, 2012, 1, 86-88.	2.1	44
41	Cancer Immunotherapy of TLR4 Agonistâ€“Antigen Constructs Enhanced with Pathogenâ€Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PDâ€L1. Small, 2019, 15, e1803993.	5.2	44
42	Coronavirus derived expression systems. Journal of Biotechnology, 2001, 88, 183-204.	1.9	40
43	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Frontiers in Immunology, 2020, 11, 586907.	2.2	40
44	Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Therapy, 2010, 17, 721-732.	2.3	38
45	Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized usingex vivomyeloid-derived suppressor cells as a readout of therapeutic efficacy. OncoImmunology, 2014, 3, e945378.	2.1	37
46	Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology Technology, 2022, 14, 100079.	0.2	37
47	Myeloid-Derived Suppressor Cells in theÂTumor Microenvironment: Current Knowledge and Future Perspectives. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 113-123.	1.0	36
48	Membrane cell fusion activity of the vaccinia virus A17?A27 protein complex. Cellular Microbiology, 2007, 10, 070816180854001-???.	1.1	34
49	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget, 0, 7, 42698-42715.	0.8	34
50	Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications. Cancers, 2013, 5, 815-837.	1.7	33
51	Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors. Journal of Immunology, 2011, 186, 4565-4572.	0.4	32
52	CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget, 2017, 8, 15789-15801.	0.8	32
53	Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. Journal of Gene Medicine, 2007, 9, 67-76.	1.4	30
54	Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance. Scientifica, 2012, 2012, 1-14.	0.6	30

#	Article	IF	Citations
55	Signaling Mechanisms that Balance Anti-viral, Auto-reactive, and Antitumor Potential of Low Affinity T Cells. Journal of Clinical & Cellular Immunology, 2013, 01, .	1.5	29
56	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 2020, 21, 2411.	1.8	28
57	Assessing T-cell responses in anticancer immunotherapy. OncoImmunology, 2013, 2, e26148.	2.1	27
58	Drafting the proteome landscape of myeloidâ€derived suppressor cells. Proteomics, 2016, 16, 367-378.	1.3	26
59	Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 29-39.	0.9	23
60	Distinct Activation Mechanisms of NF-Î²B Regulator Inhibitor of NF-Î²B Kinase (IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory Protein (cFLIP). Journal of Biological Chemistry, 2016, 291, 7608-7620.	1.6	23
61	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget, 2015, 6, 368-380.	0.8	23
62	Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. Cancers, 2019, 11, 808.	1.7	22
63	Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO₂ Chromatography. Journal of Proteome Research, 2018, 17, 1172-1182.	1.8	21
64	Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. Oncotarget, 2015, 6, 23944-23958.	0.8	21
65	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Research, 2013, 176, 1-15.	1.1	20
66	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	3.7	20
67	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunology, 2014, 7, 89-100.	2.7	19
68	Systemic CD4 immunity: A powerful clinical biomarker for PDâ€L1/PDâ€1 immunotherapy. EMBO Molecular Medicine, 2020, 12, e12706.	3.3	19
69	Kaposi's Sarcoma-Associated Herpesvirus vFLIP and Human T Cell Lymphotropic Virus Type 1 Tax Oncogenic Proteins Activate IÂB Kinase Subunit Â by Different Mechanisms Independent of the Physiological Cytokine-Induced Pathways. Journal of Virology, 2011, 85, 7444-7448.	1.5	15
70	Novel function for the p38â€MK2 signaling pathway in circulating CD1c+ (BDCAâ€1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances ILâ€12 whilst suppressing ILâ€10. International Journal of Cancer, 2014, 134, 575-586.	2.3	15
71	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5918.	1.8	15
72	Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix. Pathology International, 2015, 65, 476-485.	0.6	14

#	Article	IF	Citations
73	The transduction pattern of ILâ€12â€encoding lentiviral vectors shapes the immunological outcome. European Journal of Immunology, 2015, 45, 3351-3361.	1.6	14
74	Targeting Lentiviral Vectors for Cancer Immunotherapy. Current Cancer Therapy Reviews, 2011, 7, 248-260.	0.2	13
75	DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. International Journal of Cancer, 2013, 133, 1400-1407.	2.3	13
76	Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 51-59.	1.4	13
77	On the Mechanism of T cell receptor downmodulation and its physiological significance. The Journal of Bioscience and Medicine, 0, , 1-6.	0.4	12
78	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. Gene Therapy, 2017, 24, 370-375.	2.3	11
79	The Membrane M Protein of the Transmissible Gastroenteritis Coronavirus Binds to the Internal Core through the Carboxy-Terminus. Advances in Experimental Medicine and Biology, 2001, 494, 589-593.	0.8	11
80	TNF-Î±-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy. Frontiers in Immunology, 2022, 13, 811867.	2.2	11
81	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. Cancers, 2020, 12, 2181.	1.7	9
82	On the Mechanism of T cell receptor down-modulation and its physiological significance. The Journal of Bioscience and Medicine, 2011, 1, .	0.4	9
83	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. British Journal of Cancer, 2022, 126, 1168-1177.	2.9	9
84	Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. Molecular Therapy, 2017, 25, 504-511.	3.7	8
85	CAR-T Cells for the Treatment of Lung Cancer. Life, 2022, 12, 561.	1.1	8
86	Nature of the Virus Associated with Endemic Balkan Nephropathy. Emerging Infectious Diseases, 2002, 8, 869-870.	2.0	7
87	Immunopurification applied to the study of virus protein composition and encapsidation. Journal of Virological Methods, 2004, 119, 57-64.	1.0	7
88	Immunotherapy in malignant melanoma: recent approaches and new perspectives. Melanoma Management, 2017, 4, 39-48.	0.1	7
89	Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. Reports of Practical Oncology and Radiotherapy, 2019, 24, 221-226.	0.3	6
90	A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets. Journal of Personalized Medicine, 2021, 11, 542.	1.1	6

#	Article	IF	Citations
91	Impact of T cell selection methods in the success of clinical adoptive immunotherapy. Cellular and Molecular Life Sciences, 2014, 71, 1211-1224.	2.4	5
92	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	1.0	5
93	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. , 2014, , .		4
94	Targeted Lentiviral Vectors: Current Applications and Future Potential. , 0, , .		3
95	Constraints on General Relativity Geodesics by a Covariant Geometric Uncertainty Principle. Physics, 2021, 3, 790-798.	0.5	2
96	Lentiviral expression of GAD67 and CCK promoter-driven opsins to target interneuronsin vitroandin vivo. Journal of Gene Medicine, 2016, 18, 27-37.	1.4	1
97	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. Lung Cancer Management, 2018, 7, LMT07.	1.5	1
98	Clinical Grade Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 69-85.	0.3	1
99	Covariant Space-Time Line Elements in the Friedmannâ€“Lemaitreâ€“Robertsonâ€“Walker Geometry. Axioms, 2022, 11, 310.	0.9	1
100	Lentiviral Vectors in Immunotherapy. , 0, , .		0
101	Ex Vivo MDSC Differentiation Models. SpringerBriefs in Immunology, 2016, , 49-59.	0.1	0
102	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	0.7	0
103	Immunomodulation by Genetic Modification Using Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 51-67.	0.3	0
104	Development of Retroviral and Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 11-28.	0.3	0
105	Cell and Tissue Gene Targeting with Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 29-50.	0.3	0
106	Differentiation of Murine Myeloid-Derived Suppressor Cells. SpringerBriefs in Immunology, 2016, , 25-37.	0.1	0
107	Editorial on â€œPD-1 is a haploinsufficient suppressor of T cell lymphomagenesisâ€• Translational Cancer Research, 2018, 7, S58-S60.	0.4	0